The Qt Company Announces the Qt Automotive Suite
Today, The Qt Company, creators of the Qt cross-platform development framework, together with its partners KDAB and Pelagicore announced the Qt Automotive Suite, a new product to support common In-Vehicle-Infotainment (IVI) system development needs of automotive OEMs and Tier1’s.
Today’s automakers and suppliers want to deliver an in-car experience that keeps drivers connected and informed. An experience where they can leverage a range of devices, services and where drivers can extend their work and their home into their vehicle through the connected car. Software technology is shaping the future of automotive and the user experience is what is in focus.
By combining proven components and tools used in the industry into a single offering, The Qt Automotive Suite meets the needs of automotive software solution providers with a ready-made offering. The solution is built on the Qt toolkit which encompasses libraries, tools, hardware adaptation and ready-made components. Qt is already a tried and tested mature tool within the industry powering the IVI systems of millions of cars on the road today. This new automotive development product will make it even easier and faster for OEMs and Tier1’s go to market.
Built upon the need of the automotive industry to consolidate an ever growing and complex supply chain, the Qt Automotive Suite aims to unite and simplify the tools and software components needed to create stunning, highly-performing and quickly adaptable IVI user interfaces devices.
“When building IVI systems, we see that many automotive manufacturers and providers are facing similar challenges with managing their technical solutions. The Qt Automotive Suite provides readily available components promising productivity and a high level of quality through world-class tools. This solution promises to make automotive development effortless where the UX and hardware and operating system flexibility is at the core, in turn allowing OEMs and Tier1’s concentrate on adding end-user value instead of tackling technical details.” says Petteri Holländer, Head of Product Management for the Qt Company.
The Qt Company, Pelagicore and KDAB have experience in delivering automotive UI software to over 20 automotive customers, and now they have joined their efforts in taking the Qt technology to the next level in the industry. Together, The Qt Company, KDAB and Pelagicore have created technology that elevates Qt from being a UI and application framework to being a full-fledged automotive UI software platform. Built on top of and aligned with the widely used GENIVI automotive platform architecture and leveraging the cross-platform nature of the Qt technology, there is a significant base of developers ready to take advantage of the new offering.
Qt Automotive Suite will be available under a dual-license scheme, both open source and commercial versions. The Qt Company also invites all interested parties to participate in defining related APIs under the Qt Project governance model.
“Qt Automotive Suite delivers a modern multi-process architecture enabling stunning fluid 2D and photo-realistic 3D user experiences in combination with cloud services. The dual licensing scheme enables car makers to develop an eco-system of innovation around their IVI offerings – from concept to production. We are proud to be a key contributor to Qt Automotive Suite.” says Alwin Bakkenes, CEO of Pelagicore.
“Platform-independent IVI and cluster software is a huge opportunity for the whole automotive industry. KDAB's and Pelagicore's experience with the leading industry platforms, together with the tried and true foundation that is the Qt framework, deliver an opportunity to unify the development of automotive applications, instead of doing them on a project-by-project basis,” says Kalle Dalheimer, CEO of KDAB.
More information about the Qt Automotive Suite will be presented at the Qt World Summit 2015 (Oct 6-7, Berlin) keynotes and in-depth technical strategy sessions. To register for the event, please visit www.qt.io.
For further company information please visit: About The Qt Company
To download the company logo please click here
# # #
October 2015 Ref: DQ162/A
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151001005751/en/
Contact information
Contacts for Editorial Enquiries
The Qt Company
Petteri
Holländer
Head of Product Management
+358 4 05 15 85 45
Petteri.Hollander@theqtcompany.com
or
Pinnacle
Marketing Communications
Nevena Rasic
+44 (0) 2084 296 541
n.rasic@pinnaclemarcom.com
About Business Wire
Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com